Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,850 result(s) found for: Breast cancer. Displaying page 6 of 93.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-004112-11 Sponsor Protocol Number: C/31/2014 Start Date*: 2015-05-20
    Sponsor Name:Imperial College London
    Full Title: ALERT: A phase II study of alternating eribulin and hormonal therapy in pre-treated ER+ve breast cancer
    Medical condition: Patients with locally advanced or metastatic oestrogen receptor positive (ER+ve) breast cancer who have received at least one hormonal therapy and at least one chemotherapy in the metastatic setting.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015999-10 Sponsor Protocol Number: XM22-03 Start Date*: 2010-03-02
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study
    Medical condition: Breast cancer high risk stage II, III or IV according to AJCC classification
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006200 Breast cancer stage II PT
    12.0 10006201 Breast cancer stage III PT
    12.0 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-018090-30 Sponsor Protocol Number: 09SEIN09 Start Date*: 2010-01-27
    Sponsor Name:Institut Claudius Regaud
    Full Title: Hormonothérapie adjuvante du cancer du sein : Pharmacocinétique du tamoxifène et des anti-aromatases, corrélation avec les caractéristiques pharmacogénétiques Protocole PHACS (Pharmacologie de l’Ho...
    Medical condition: Cancer du sein en situation adjuvante
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002998-21 Sponsor Protocol Number: CLEE011O12301C Start Date*: 2019-02-25
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, multicenter, randomized, open-label trial toevaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-...
    Medical condition: hormone receptor-positive, HER2-negative, early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006203 Breast cancer stage unspecified LLT
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) IE (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-007089-12 Sponsor Protocol Number: 2606 B Start Date*: 2007-02-07
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women
    Medical condition: Metastased breast cancer, first line treatment, for women with age>70 years old,Her2 positive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003620-11 Sponsor Protocol Number: SBG-2-01 Start Date*: 2006-10-10
    Sponsor Name:Biotec Pharmacon ASA
    Full Title: A phase I/II study to assess the effect of soluble beta-1,3/1,6-glucan in combination with standard therapy in patients with breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002759-15 Sponsor Protocol Number: XEL-CONT-VS ESTANDAR Start Date*: 2004-11-15
    Sponsor Name:Dr. Miguel Martín
    Full Title: Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patients
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027475 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000900-34 Sponsor Protocol Number: VA 2007-09 Start Date*: 2007-07-10
    Sponsor Name:Centre Val d'Aurelle - Paul Lamarque
    Full Title: Essai randomisé, en double aveugle, chez les femmes ménopausées ayant un cancer du sein RE+ comparant deux traitements néo-adjuvants : un anti-aromatase (Letrozole) VS un SERM (Tamoxifène). Effet ...
    Medical condition: Le cancer du sein est le cancer féminin le plus fréquent en Europe représentant 28% de tous les cancers féminins. Son incidence y est de l’ordre de 70 pour 100 000 femmes. Sa fréquence est stable (...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002018-37 Sponsor Protocol Number: BO27938 Start Date*: 2013-04-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BRE...
    Medical condition: HER2-positive primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) IE (Prematurely Ended) ES (Ongoing) GR (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006943-29 Sponsor Protocol Number: 2006.453/46 Start Date*: 2009-01-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: ESSAI RANDOMISE, EN DOUBLE AVEUGLE CONTRE PLACEBO EVALUANT L’EFFICACITE DU RISEDRONATE ORAL 35 MG PAR SEMAINE DANS LA PREVENTION DE LA PERTE OSSEUSE CHEZ LA FEMME ATTEINTE D’UN CANCER DU SEIN TRAIT...
    Medical condition: Cancer du sein
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    9.1 10027308 Menopause LLT
    9.1 10049088 Osteopenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003620-32 Sponsor Protocol Number: MNEMOSYNE-0712 Start Date*: 2008-11-20
    Sponsor Name:Centre Oscar Lambret
    Full Title: Etude Prospective Randomisée Ouverte et Multicentrique évaluant les effets sur les fonctions cognitives de l’hormonothérapie adjuvante dans le cancer du sein de la femme ménopausée
    Medical condition: Cancer du sein non métastatique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005885-36 Sponsor Protocol Number: 0007 Start Date*: 2006-02-09
    Sponsor Name:AZIENDA USL DI FORLI
    Full Title: Dose finding study of Liposomal Doxorubicin Myocet in combination with Capecitabine Xeloda in the treatment of metastatic breast cancer patients
    Medical condition: Metastatic breast cancer pretreated
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002736-28 Sponsor Protocol Number: GINECO-BR106 Start Date*: 2007-09-19
    Sponsor Name:ARCAGY-GINECO
    Full Title: A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old wi...
    Medical condition: Breast cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003509-41 Sponsor Protocol Number: GBG90 Start Date*: 2016-08-01
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien...
    Medical condition: Patients with triple negative or HRpositive, early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018389-22 Sponsor Protocol Number: LAP113957 / SOLTI-1001 Start Date*: 2010-09-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compar...
    Medical condition: patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Prematurely Ended) FR (Completed) NO (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014773-40 Sponsor Protocol Number: AVASTEM/IPC2009-001 Start Date*: 2010-01-04
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: Essai de phase II de preuve du concept : Evaluation de l’activité anti-cellules souches cancéreuses du bevacizumab administré en combinaison à la chimiothérapie néoadjuvante dans les cancers du sein
    Medical condition: Tumeurs du sein localement avancées ou inflammatoires candidates à un traitement néo-adjuvant par une association séquentielle FEC/docetaxel .
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005173-56 Sponsor Protocol Number: GOG/2007-01 Start Date*: 2008-03-06
    Sponsor Name:Grupo Oncológico Gallego (GOG)
    Full Title: ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, EN FASE II, DE TRATAMIENTO SECUENCIAL CON TAXOTERE® (T) SEGUIDO DE MYOCET® Y CICLOFOSFAMIDA (MC), COMO TRATAMIENTO ANTINEOPLASICO PRIMARIO EN PACIENTES CON ...
    Medical condition: Cáncer de mama localizado (estadio II y IIIa).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011037-27 Sponsor Protocol Number: ML22197/2009-01 Start Date*: 2009-05-27
    Sponsor Name:Instituto Científico Tecnológico de Navarra (ICTN)
    Full Title: Estudio fase II, multicéntrico, para evaluar los marcadores predictores de respuesta en cáncer de mama localmente avanzado, tratado con bevacizumab en combinación con quimioterapia neoadyuvante.
    Medical condition: Cancer Mama localmente avanzado
    Disease: Version SOC Term Classification Code Term Level
    9 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005858-23 Sponsor Protocol Number: PROMIX Start Date*: 2008-03-12
    Sponsor Name:PROMIX Trial Group
    Full Title: Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early
    Medical condition: Patients diagnosed with breast cancer who are candidates for preoperative (neoadjuvant) chemotherapy due to localized primary breast cancer including inflammatory breast cancer suitable for primary...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006200 Breast cancer stage II LLT
    9.1 10006201 Breast cancer stage III LLT
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004169-16 Sponsor Protocol Number: ML20382 Start Date*: 2007-11-15
    Sponsor Name:Roche Farma, S.A.
    Full Title: Estudio fase II multicéntrico, abierto, no aleatorizado para evaluar la eficacia de una combinación con bevacizumab y quimioterapia secuencial, como tratamiento de pacientes con cáncer de mama oper...
    Medical condition: Adenocarcinoma de mama operable HER2 negativo, de más de 2 cm de tamaño, no tratado previamente.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 13:29:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA